Advertisement

Drugs

, Volume 73, Issue 15, pp 1723–1732 | Cite as

Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer

  • Mark Sanford
Adis Drug Evaluation

Abstract

Enzalutamide (MDV3100, XTANDI®) is an androgen receptor inhibitor that is indicated for the treatment of metastatic, castration-resistant, prostate cancer (mCRPC) that has progressed despite treatment with docetaxel. This article reviews the pharmacology, efficacy and tolerability of enzalutamide relevant to this indication. In a randomized, double-blind, placebo-controlled, multinational, phase III trial in patients with mCRPC progressing after docetaxel therapy, enzalutamide significantly prolonged overall survival (OS), delayed prostate specific antigen progression and prolonged radiographic progression-free survival and time to the first skeletal event. The median OS was 18.4 months in the enzalutamide group and 13.6 months in the placebo group, which represents a 37 % reduction in the mortality risk in the enzalutamide group. Enzalutamide was also associated with significant benefits in health-related quality of life and in pain palliation. Enzalutamide was generally as well tolerated as placebo during the trial, with most adverse events at a mild or moderate level of severity. Enzalutamide carries a small increased risk of seizures that appears to be dose-dependent. Enzalutamide is an efficacious and well tolerated treatment for this severe, rapidly progressive disease.

Keywords

Overall Survival Docetaxel Androgen Deprivation Therapy Abiraterone Enzalutamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012;29:871–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs. 2012;72(8):1011–28.PubMedCrossRefGoogle Scholar
  4. 4.
    Ong M, Winquist E. Recent advances in second-line treatment of castration-resistant prostate cancer. Curr Opin Support Palliat Care. 2011;5(3):199–205.PubMedCrossRefGoogle Scholar
  5. 5.
    Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. 2013. https://www.auanet.org/common/pdf/education/clinical-guidance/Castration-Resistant-Prostate-Cancer.pdf. Accessed 23 Sept 2013.
  6. 6.
    Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.PubMedCrossRefGoogle Scholar
  7. 7.
    De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population; a systematic review. Int J Clin Pract. 2011;65(11):1180–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Sullivan PW, Mulani PM, Fishman M, et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16(4):571–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. Eur Urol. 2012;61(5):950–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Tsao C-K, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(11):1580–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Yang LPH. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(15):2067–77.PubMedCrossRefGoogle Scholar
  13. 13.
    Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(1):101–8.PubMedCrossRefGoogle Scholar
  14. 14.
    National Cancer Institute, National Institutes of Health. FDA approval for radium 223 dichloride. 2013. http://cancer.gov/cancertopics/druginfo/fda-radium-223-dichloride. Accessed 4 Sept 2013.
  15. 15.
    Astellas Pharma US, Inc. XTANDI® (enzalutamide) capsules for oral use: US prescribing information. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf. Accessed 23 Sept 2013.
  16. 16.
    European Medicines Agency. Xtandi 40 mg soft capsules: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639.pdf. Accessed 28 Aug 2013.
  17. 17.
    Astellas Pharma. XTANDI® (Enzalutamide) capsules receives Health Canada approval for treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel [media release] 4 June 2013. http://www.astellas.com.
  18. 18.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Hörnberg E, Ylitalo EB, Cmalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011. doi: 10.1371/journal.pone.0019059.Google Scholar
  20. 20.
    Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA. 2010;107(39):16759–65.PubMedCrossRefGoogle Scholar
  23. 23.
    Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013; 2:e00499.Google Scholar
  24. 24.
    Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437–46.PubMedCrossRefGoogle Scholar
  25. 25.
    Guerrero J, Alfaro IE, Gomez F, et al. Enzalutamide, an androgen receptor signalling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12):1291–305.PubMedCrossRefGoogle Scholar
  26. 26.
    Nadiminty N, Tummala R, Liu C, et al. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12(8):1629–37.PubMedCrossRefGoogle Scholar
  27. 27.
    Toren P, Kim S, Gleave M, et al. Combined targeting of PI3K/AKT and AR pathway with AZD5363 and enzalutamide induces anticancer activity in preclinical models of prostate cancer [abstract no. 982]. J Urol. 2013;189(4 Suppl):e403.CrossRefGoogle Scholar
  28. 28.
    Fleming MT, Rathkopf DE, Gibbons J, et al. Enzalutamide (ENZA) in combination with docetaxel in men with prostate cancer: preliminary results from a phase I study [abstract no. 63]. J Clin Oncol. 2013; 31(6 Suppl 1).Google Scholar
  29. 29.
    Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377–90.PubMedGoogle Scholar
  30. 30.
    Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedCrossRefGoogle Scholar
  31. 31.
    de Bono J, Fizazi K, Shore N, et al. Assessing the impact of prior treatments on the efficacy of enzalutamide (ENZ): a subanalysis of the phase 3 AFFIRM trial (abstract). 38th European Society for Medical Oncology Annual Meeting; 27 September–1 October 2013, Amsterdam.Google Scholar
  32. 32.
    Scher H, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor [abstract no. 6]. J Clin Ocol. 2013;31(6 Suppl 1).Google Scholar
  33. 33.
    Sternberg CN, De Bono JS, Chi KN, et al. Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract no. 16]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
  34. 34.
    Saad F, De Bono JS, Shore ND, et al. Efficacy outcomes by baseline prostate-specific antigen (PSA): results from the phase 3 AFFIRM trial [abstract no. 785]. 108th Annual Meeting of the American Urological Association; 2013; San Diego, CA.Google Scholar
  35. 35.
    Loriot Y, Fizazi K, De Bono J, et al. Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial [abstract no. 5065]. J Clin Oncol. 2013;31(15 Suppl 1).Google Scholar
  36. 36.
    Miller K, Scher HI, Fizazi K, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 17]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
  37. 37.
    Fizazi K, Scher HI, Saad F, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (Sre) and pain in the phase 3 Affirm study [abstract no. 8960]. 37th Congress of the European Society for Medical Oncology, 2012, Vienna.Google Scholar
  38. 38.
    Data on file, Astellas Pharma, 2013.Google Scholar
  39. 39.
    Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy: phase II study results in patients with hormone-naive prostate cancer [abstract no. 18]. J Clin Oncol. 2013;31(6 Suppl 1).Google Scholar
  40. 40.
    Medivation, Inc. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). 2013. http://clinicaltrials.gov/show/NCT01212991. Accessed 23 Sept 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations